Product Description: Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70.
CAS Number: 1365287-97-3
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: c-Met/HGFR